Class / Patent application number | Description | Number of patent applications / Date published |
514217110 | Nitrogen or C(=X), wherein X is chalcogen, bonded directly to the seven-membered hetero ring | 31 |
20090018116 | Therapeutic Compounds - Compounds of formula I or pharmaceutically acceptable salts thereof: | 01-15-2009 |
20090023710 | Compound - There is provided a compound having Formula (I) wherein each of R | 01-22-2009 |
20090181951 | PARP INHIBITORS - A compound of the formula (I), and pharmaceutically acceptable salts thereof, wherein: R | 07-16-2009 |
20090203675 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). | 08-13-2009 |
20090209520 | 2 -OXYBENZAMIDE DERIVATIVES AS PARP INHIBITORS - A compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein: R | 08-20-2009 |
20090264414 | Amide Derivatives and Pharmaceutical Use Thereof - The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. | 10-22-2009 |
20090281085 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY - Compounds according to the formula below are disclosed herein: | 11-12-2009 |
20100016291 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES - The present invention is concerned with novel tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes. Formula (I). | 01-21-2010 |
20100056497 | AMIDE DERIVATIVE - The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. | 03-04-2010 |
20100063030 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 03-11-2010 |
20100113423 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 05-06-2010 |
20100168083 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME - Novel substituted adamantane based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome. | 07-01-2010 |
20100179131 | Combination treatment for diabetes mellitus - The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1. | 07-15-2010 |
20110015184 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (Ia): | 01-20-2011 |
20110098281 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 04-28-2011 |
20110112076 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS - The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I). | 05-12-2011 |
20120046276 | Tuberculosis treatment using pleuromutilin derivatives - A method of preventing or treating diseases caused by | 02-23-2012 |
20120295890 | GLYCOSAMINOGLYCAN INHIBITORS - Provided herein are chondroitin sulfate inhibitors, including modulators of glycosylation, and/or sulfation of galactose or N-acetyl galactosamine glycosaminoglycans. | 11-22-2012 |
20130018044 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOFAANM Guichou; Jean-FrancoisAACI MontpellierAACO FRAAGP Guichou; Jean-Francois Montpellier FRAANM Colliandre; LionelAACI Orleans Cedex 2AACO FRAAGP Colliandre; Lionel Orleans Cedex 2 FRAANM Ahmed-Belkacem; HakimAACI CreteilAACO FRAAGP Ahmed-Belkacem; Hakim Creteil FRAANM Pawlotsky; Jean-MichelAACI CreteilAACO FRAAGP Pawlotsky; Jean-Michel Creteil FR - The present invention relates to a compound of formula (I): | 01-17-2013 |
20130184262 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF - The present invention provides compounds of Formula (I): | 07-18-2013 |
20130203738 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) - The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. | 08-08-2013 |
20140073632 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS - Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell. | 03-13-2014 |
20140179687 | New Inhibitors of Cyclophilins and Uses Thereof - The present invention relates to a compound of formula (I): | 06-26-2014 |
20140275037 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). | 09-18-2014 |
20140275038 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140275039 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140303150 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES - The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis. | 10-09-2014 |
20140371209 | S1P Modulating Agents - Compounds of formula (I) or (II) can modulate the activity of SIP receptors. | 12-18-2014 |
20150038493 | COMPOUNDS THAT TRAP ALPHA-OXOALDEHYDES AND ALPHA-BETA-UNSATURATED ALDEHYDES, META-COMPOUNDS CONTAINING SUCH COMPOUNDS, AND USE OF SAID COMPOUNDS IN TREATING ILLNESSES RELATED TO THE ACCUMULATION OF AGES AND ALES - The present invention relates to a series of molecules derived from 2,3-diaminopropionic acid (DAP), comprising or not comprising an 8-hydroxyquinoline (8-HQ) motif, and to the use of said molecules for trapping an alpha-oxoaldehyde resulting particularly from the degradation of the glucose or for trapping an alpha-beta-unsaturated aldehyde, resulting particularly from the oxidative degradation of fatty acids. These molecules can have a further application in the fields of cosmetics, food processing, and pharmaceuticals. | 02-05-2015 |
20150133431 | GGA DERIVATIVES - This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives. | 05-14-2015 |
20220133671 | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE - The present disclosure relates to methods of preventing or inhibiting fibrosis using small molecule sialidase inhibitors. The present disclosure also relates to methods treating obesity, liver inflammation, steatosis, and cancer. These methods can involve administering the compounds to a patent at risk of developing fibrosis inflammation, obesity, steatosis, or cancer, in a manner that inhibits NEU3. | 05-05-2022 |